SIGLEC1 and myeloid sarcoma: A second study by Bogie et al.12 again identified small (approximately twofold) increases in SIGLEC1 expression on monocytes in 57 MS patients and found that these increases were independent of progressive disease and also of interferon treatment, an observation that is at odds with our own findings and biological plausibility.